




9. MECHANISMS OF DEVELOPMENT I – REGULATION OF LIMB DEVELOPMENT BY FIBROBLAST GROWTH FACTORS (FGF)

4 receptors: FGFR1-4
22 ligands: FGF1-23







Initiation: *Tbx5* - dependent





A Induction








B Progression




Outgrowth: *Tbx5* - independent








a Normal FL and HL




AER KO mutant phenotypes


b Fgf8 single KO FL



c Fgf4; Fgf8 double KO FL




d Fgf8 single KO HL




e Fgf4; Fgf8 double KO HL





How do the limbs grow?



FGFR3






FGFR3-related skeletal dysplasia

STATURE

Hypochondroplasia
Achondroplasia
SADDAN
Thanatophoric Dysplasia






FGFR3-related skeletal dysplasia



Achondroplasia



Thanatophoric Dysplasia



healthy



TD



- short long bones
- brachydactyly
- macrocephaly
- low nasal bridge
- spinal stenosis
- temporal lobe malformations




Loss-of-function

vs. Gain-of-function







healthy





TD


FGFR3 inhibits chondrocyte proliferation by arresting their cell cycle in G1 phase




....via inhibition of cdk activity necessary for progression through the G1 phase of a cell cycle




FGF alters the cartilage-like phenotype of chondrocytes






.....via MMP-mediated degradation of extracellular matrix




FGF2 activates Erk and p38 MAPK, PLC γ and PKB in chondrocytes






.....but only Ras/Erk activity is involved in FGF-induced growth arrest



Erk MAP kinase activity is necessary for FGFR3 phenotype in cartilage



C-type Natriuretic Peptide (CNP) over-expression results in skeleton overgrowth in mice




wild-type

CNP↑



CNP over-expression???

CNP rescues dwarfism caused by ACH mutation in FGFR3




wild-type

Fgfr3^{Ach}



Fgfr3^{Ach/CNP} ↑

CNP counteracts FGF2-mediated chondrocyte growth arrest through cGMP-dependent pathway





CNP antagonizes FGF2-mediated loss of cartilage extracellular matrix in chondrocytes



unstimulated



control









CNP




pCPT-
cGMP


FGF2




CNP counteracts FGF2-mediated activation of Erk MAP kinase in chondrocytes







CNP inhibits Erk MAP kinase module at the Raf level




Is protein kinase C (PKC) involved in FGFR3-mediated activation of Erk in chondrocytes?









Protein kinase C inhibitor Bisindolylmaleimide I (Bis I) suppresses the FGF2-mediated activation of Erk MAP kinase pathway in chondrocytes by preventing the SHP2 association with FRS2 and Gab1 adaptor proteins




FGFR3 associates with STAT1 and acts as STAT1-kinase in chondrocytes




Chronic FGF stimulus inhibits cytokine/STAT signaling in chondrocytes




Chronic FGF stimulus inhibits cytokine/STAT signaling in chondrocytes



FGF2 causes premature senescence in chondrocytes



FGF2 signals towards the cytoskeleton in chondrocytes




Where is Wnt?




I Wnt YOU

FGF2: C1 15' 1h 3h 6h 12h 24h 48h 72h C2 C3


b-catenin



actin



2001



2008

